Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

This article has been updated

Abstract

Intraperitoneal treatment with interferon-γ (IFN-γ) has been shown to achieve surgically documented responses in the second-line therapy of ovarian cancer. To assess its efficacy in the first-line therapy, we conducted a randomized controlled trial with 148 patients who had undergone primary surgery for FIGO stage Ic–IIIc ovarian cancer. In the control arm women received 100 mg m–2cisplatin and 600 mg m–2cyclophosphamide, the experimental arm included the above regimen with IFN-γ 0.1 mg subcutaneously on days 1, 3, 5, 15, 17 and 19 of each 28-day cycle. Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82). Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached). Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.). Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ. Thus, with acceptable toxicity, the inclusion of IFN-γ in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival. © 2000 Cancer Research Campaign

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C and Mantovani A (1990) Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50: 7318–7323

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Aulitzky W, Gastl G, Aulitzky WE, Nachbaur K, Lanske B, Kemmler G, Flener R, Frick J and Huber C (1987) Interferon-γ for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology 176: 85–95

    CAS  Article  PubMed Central  Google Scholar 

  3. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ and Zighelboim J (1985) Intraperitoneal recombinant α-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res 45: 4447–4453

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Billiau A (1996) Interferon-γ: biology and role in pathogenesis. Adv Immunol 62: 61–130

    CAS  Article  PubMed Central  Google Scholar 

  5. Boehm U, Klamp T, Groot M and Howard JC (1997) Cellular responses to interferon-γ. Annu Rev Immunol 15: 749–795

    CAS  Article  PubMed Central  Google Scholar 

  6. Colombo N, Peccatori F, Paganin C, Bini S, Brandley M, Mangioni C, Mantovani A and Allavena P (1992) Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 51: 42–46

    CAS  Article  PubMed Central  Google Scholar 

  7. D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W and Lewis JL (1988) A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6: 689–695

    CAS  Article  PubMed Central  Google Scholar 

  8. Dighe AS, Richards E, Old LJ and Schreiber RD (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1: 447–456

    CAS  Article  PubMed Central  Google Scholar 

  9. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diaminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575–4580

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ and Schreiber RD (1998) Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556–7561

    CAS  Article  PubMed Central  Google Scholar 

  11. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU and Fidler IJ (1986) Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with recombinant γ-interferon. Cancer Res 46: 5401–5405

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Malik STA, Knowles RG, East N, Lando D, Stamp G and Balkwill FR (1991) Antitumor activity of γ-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 51: 6643–6649

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K and Steis RG (1988) The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434–445

    CAS  Article  PubMed Central  Google Scholar 

  14. Mannel DN and Falk W (1983) Interferon-gamma is required in activation of macrophages for tumor cytotoxicity. Cell Immunol 79: 396–402

    CAS  Article  PubMed Central  Google Scholar 

  15. Marth C, Fuith LC, Böck G, Daxenbichler G and Dapunt O (1989) Modulation of ovarian carcinoma tumor marker CA-125 by γ-interferon. Cancer Res 49: 6538–6542

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE and Daxenbichler G (1990) γ-interferon reduces expression of the protooncogen c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50: 7037–7041

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, Offner F, Feichtinger H, Zwierzina H and Daxenbichler G (1996) Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67: 826–830

    CAS  Article  PubMed Central  Google Scholar 

  18. Marth C, Widschwendter M, Kærn J, Jørrgensen N-P, Windbichler G, Zeimet AG, Tropé C and Daxenbichler G (1997) Cisplatin resistance is associated with reduced interferon-γ-sensitivity and increased HER-2 expression in cultured ovarian cancer cells. Br J Cancer 76: 1328–1332

    CAS  Article  PubMed Central  Google Scholar 

  19. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6

    CAS  Article  Google Scholar 

  20. Nehmé A, Julia AM, Jozan S, Chevreau C, Bugat R and Canal P (1994) Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur J Cancer 30A: 550–525

  21. Ozols RF, Rubin SC, Thomas G and Robboy S (1997) Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology, 2nd edn, Hoskins WJ, Perez CA and Young RC (eds), 919–986, Lippincott-Raven: Philadelphia

    Google Scholar 

  22. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S and Brandely M (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 14: 343–350

    CAS  Article  PubMed Central  Google Scholar 

  23. Saito T, Berens ME and Welander CE (1986) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 46: 1142–1147

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Weisenthal LM, Dill PL and Pearson FC (1991) Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J Natl Cancer Inst 83: 37–42

    CAS  Article  PubMed Central  Google Scholar 

  25. Welander CE, Homesley HD, Reich SD and Levin EA (1988) A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 11: 465–469

    CAS  Article  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Windbichler, G., Hausmaninger, H., Stummvoll, W. et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82, 1138–1144 (2000). https://doi.org/10.1054/bjoc.1999.1053

Download citation

Keywords

  • randomized phase III trial
  • multicentre study
  • ovarian cancer
  • interferon-type II

Further reading

Search

Quick links